Ousia Pharma raised Seed funding from Omega Funds to support its dual-incretin-NMDA receptor antagonist's preclinical and clinical development.

May 06, 2025•2 months ago

Round Type

seed

CopenhagenPharmaceuticalBiotechnologyHealth Care

Investors

Omega Funds

Description

Ousia Pharma, a Copenhagen-based biotech company, raised an undisclosed amount in Seed funding. Omega Funds made the investment to help develop its innovative treatment for obesity. The company is also welcoming new board members from AstraZeneca's leadership. This funding will support the development of its once-weekly drug conjugate.

Company Information

Company

Ousia Pharma

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Ousia Pharma is a Copenhagen-based biotech company focused on developing a new drug class for obesity. The company creates peptide-drug conjugates that utilize incretin hormone analogues to target the brain's appetite control centers. Ousia Pharma aims to address obesity and metabolic diseases through innovative therapeutic approaches. Led by CEO Anders B. Klein, the company has emerged from the University of Copenhagen.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Ousia Pharma raised Seed funding from Omega Funds to support its dual-incretin-NMDA receptor antagonist's preclinical and clinical development.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information